Literature DB >> 16768644

Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome.

Sol Jaworowski1, Fortu Benarroch, Varda Gross-Tsur.   

Abstract

Atomoxetine and OROS methylphenidate were successfully used concomitantly in a 10-year-old boy suffering from attention-deficit/hyperactivity disorder (ADHD) with comorbid bipolar disorder and Tourette syndrome (TS). The child received valproic acid, clonidine, and ziprasidone concurrently. Because possible side effects of pharmacological treatment for one diagnosis may exacerbate a comorbid condition, contingent management strategies, when using polypharmacy, are mandated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16768644     DOI: 10.1089/cap.2006.16.365

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  7 in total

1.  Atomoxetine and stimulant medications in children and adolescents with persistent symptoms of attention deficit hyperactivity disorder despite monotherapy.

Authors:  Amanda Jacques
Journal:  Can Pharm J (Ott)       Date:  2012-09

2.  ADHD-juvenile bipolar disorder: mimics and chameleons!

Authors:  Ahmed Naguy
Journal:  World J Pediatr       Date:  2018-02-14       Impact factor: 2.764

3.  National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007.

Authors:  Jonathan S Comer; Mark Olfson; Ramin Mojtabai
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2010-09-01       Impact factor: 8.829

4.  Performance on a strategy set shifting task during adolescence in a genetic model of attention deficit/hyperactivity disorder: methylphenidate vs. atomoxetine treatments.

Authors:  Roxann C Harvey; Chloe J Jordan; David H Tassin; Kayla R Moody; Linda P Dwoskin; Kathleen M Kantak
Journal:  Behav Brain Res       Date:  2013-01-31       Impact factor: 3.332

Review 5.  Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions.

Authors:  Grazia Dell'Agnello; Alessandro Zuddas; Gabriele Masi; Paolo Curatolo; Dante Besana; Andrea Rossi
Journal:  CNS Drugs       Date:  2009-09       Impact factor: 5.749

Review 6.  A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.

Authors:  Tamás Treuer; Susan Shur-Fen Gau; Luis Méndez; William Montgomery; Julie A Monk; Murat Altin; Shenghu Wu; Chaucer C H Lin; Héctor J Dueñas
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-04-06       Impact factor: 2.576

Review 7.  Off-label use of atomoxetine in adults: is it safe?

Authors:  Rana Dadashova; Peter H Silverstone
Journal:  Ment Illn       Date:  2012-09-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.